Applied Therapeutics Inc
$ 0.10
0.00%
24 Feb - close price
- Market Cap 14,863,000 USD
- Current Price $ 0.10
- High / Low $ 0.10 / 0.10
- Stock P/E N/A
- Book Value N/A
- EPS -0.10
- Next Earning Report 2026-03-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.88 %
- ROE -6.80 %
- 52 Week High 1.50
- 52 Week Low 0.09
About
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to combat cardiovascular disease, galactosemia, and diabetes complications. The company is headquartered in New York, New York.
Analyst Target Price
$0.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-13 | 2025-05-07 | 2024-12-31 | 2024-11-07 | 2024-08-07 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.13 | -0.15 | 0.3281 | 0.33 | -0.48 | 0.02 | -0.67 | -0.34 | -0.47 | -0.37 | -0.18 | -0.16 |
| Estimated EPS | -0.14 | -0.17 | -0.185 | -0.1667 | -0.16 | -0.16 | -0.16 | -0.23 | -0.26 | -0.26 | -0.31 | -0.46 |
| Surprise | 0.01 | 0.02 | 0.5131 | 0.4967 | -0.32 | 0.18 | -0.51 | -0.11 | -0.21 | -0.11 | 0.13 | 0.3 |
| Surprise Percentage | 7.1429% | 11.7647% | 277.3514% | 297.9604% | -200% | 112.5% | -318.75% | -47.8261% | -80.7692% | -42.3077% | 41.9355% | 65.2174% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1175 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APLT
2026-02-05 07:30:12
Applied Therapeutics (APLT) completed a merger on February 3, 2026, leading to its voluntary delisting from Nasdaq and cessation of public reporting obligations. Following the merger, corporate control shifted to the buyer's leadership, with James Harrison becoming the sole director and president. Analysts currently rate APLT as a "Sell" with a $0.09 price target due to weak financial performance and bearish technical signals.
2026-02-04 09:29:48
Applied Therapeutics (APLT) announced its delisting from Nasdaq after the consummation of a merger. The company has requested a suspension of trading and will file a Form 25 to delist and deregister its shares. Consequently, APLT also intends to file a Form 15 to suspend its SEC reporting obligations.
2026-02-04 08:34:49
Cycle Pharmaceuticals has finalized its acquisition of Applied Therapeutics, a biopharmaceutical company focusing on rare disease treatments. This strategic move, which involved a tender offer and contingent value rights, enhances Cycle's rare disease pipeline with candidates like govorestat. The acquisition aligns with Cycle's mission to address unmet medical needs in underserved patient populations.
2026-02-03 13:58:40
Cycle Group Holdings Limited has completed its acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company specializing in rare metabolic diseases. This acquisition, funded from cash reserves, brings Applied's lead drug candidate govorestat into Cycle's portfolio, expanding their focus on conditions with no current FDA-approved treatments. Applied Therapeutics, whose market capitalization was around $15.7 million at the time of acquisition, previously saw its stock fall over 80% in the past year.
2026-02-03 13:58:40
Cycle Pharmaceuticals has announced the acquisition of Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company. This acquisition expands Cycle's focus on rare metabolic diseases, bringing Applied's lead drug candidate, govorestat, which targets conditions like Classic Galactosemia and CMT-SORD, into its portfolio. The deal was funded from cash on hand, reinforcing Cycle's commitment to providing treatments for underserved rare disease communities.
2026-02-03 13:58:40
Applied Therapeutics, Inc. (APLT) announced significant board and management changes on February 3, 2026, following a merger. Several key individuals resigned from their director and officer roles, while James Harrison and Andrea Reiner were appointed as Director, President and Secretary, respectively, as part of the transitions related to the merger. These changes are detailed in an SEC 8-K filing.
